The role of PI 3‐kinase p110β in AKT signally, cell survival, and proliferation in human prostate cancer cells
- 7 January 2010
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 70 (7) , 755-764
Abstract
BACKGROUND: Class IA PI 3‐kinases produce phosphatidylinositol (3,4,5)‐trisphosphate (PIP3). PIP3 is bound by AKT which facilities its activation by PDK1. Activated AKT promotes cell survival and stimulates cell proliferation. Class IA PI 3‐kinases are heterodimers consisting of a regulatory subunit p85 and a catalytic subunit p110. The p110α isoform has been shown to be mutated in a number of tumor types. A number of recent studies suggest that the p110β isoform may be functionally relevant in prostate cancer. In this study we extend this work to include the examination of the expression and functional properties of p110α and p110β in three different prostate cancer cell lines, DU145, LNCaP, PC3, as well as the non‐tumorigenic but immortalized RWPE1 prostate epithelial cell line.METHODS: Western blot analysis was used to measure protein expression and quantitative real‐time PCR was used to measure mRNA levels. After targeted knockdown using isoform‐specific siRNAs to reduce PI 3‐kinase p110α or p110β isoform expression, we measured downstream signally events such as phosphorylation of AKT, ERK 1/2, PDK, and FOXO, as well as biological consequences such as changes in apoptosis, and alterations in cell cycle progression.RESULTS: In all three prostate cancer cell lines examined, targeted knockdown of p110β, and not p110α, resulted in significantly reduced AKT, PDK, and FOXO phosphorylation. While knockdown of either p110 isoform resulted in an increase in apoptosis and a cell cycle arrest in G1 in the remaining non‐apoptotic cells, these effects were much more pronounced with knockdown of p110β.CONCLUSIONS: Our results support the concept that p110β appears to be the predominant functional class I PI 3‐kinase isoform in prostate cancer cells. Prostate 70: 755–764, 2010.Keywords
Funding Information
- Howard University New Faculty Fund
- Charles and Mary Latham Trust Fund
- Specialized Neuroscience Research Program (NIH/NINDS U54 NS-39407)
- RCMI Grant (G12 RR03062)
- Georgia Research Alliance
- NIH/NCI (U54CA091409)
This publication has 41 references indexed in Scilit:
- Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activityProceedings of the National Academy of Sciences, 2007
- The p110α isoform of PI3K is essential for proper growth factor signaling and oncogenic transformationProceedings of the National Academy of Sciences, 2006
- Human Tumor Mutants in PI3K p110α SubunitCell Cycle, 2006
- Constitutive activation of PI3K-Akt and NF-κB during prostate cancer progression in autochthonous transgenic mouse modelThe Prostate, 2005
- The phosphatidylinositol 3-Kinase–AKT pathway in human cancerNature Reviews Cancer, 2002
- A specific function for phosphatidylinositol 3-kinase α (p85α-p110α) in cell survival and for phosphatidylinositol 3-kinase β (p85α-p110β) in de novo DNA synthesis of human colon carcinoma cellsOncogene, 2000
- Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancerOncogene, 2000
- The lipid phosphatase activity of PTEN is critical for its tumor supressor functionProceedings of the National Academy of Sciences, 1998
- Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activationBiochemical Journal, 1998
- PTEN , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate CancerScience, 1997